ANRO Quote, Financials, Valuation and Earnings

Brainstorm Cell Therapeutics, Inc. has a net margin of -- compared to Alto Neuroscience, Inc.'s net margin of --. Alto Neuroscience, Inc.'s return on equity of -45.08% beat Brainstorm Cell Therapeutics, Inc.'s return on equity of --.

Alto Neuroscience, Inc. has a consensus price target of $29.25, signalling upside risk potential of 117.8%. On the other hand Brainstorm Cell Therapeutics, Inc. has an analysts' consensus of $20.68 which suggests that it could grow by 3345.83%. Given that Brainstorm Cell Therapeutics, Inc. has higher upside potential than Alto Neuroscience, Inc., analysts believe Brainstorm Cell Therapeutics, Inc. is more attractive than Alto Neuroscience, Inc..

Alto Neuroscience, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Brainstorm Cell Therapeutics, Inc. has a beta of -0.928, suggesting its less volatile than the S&P 500 by 192.842%.

Alto Neuroscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Brainstorm Cell Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alto Neuroscience, Inc. pays -- of its earnings as a dividend. Brainstorm Cell Therapeutics, Inc. pays out -- of its earnings as a dividend.

Alto Neuroscience, Inc. quarterly revenues are --, which are smaller than Brainstorm Cell Therapeutics, Inc. quarterly revenues of --. Alto Neuroscience, Inc.'s net income of -$14.2M is lower than Brainstorm Cell Therapeutics, Inc.'s net income of -$2.1M. Notably, Alto Neuroscience, Inc.'s price-to-earnings ratio is -- while Brainstorm Cell Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alto Neuroscience, Inc. is -- versus -- for Brainstorm Cell Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI Corp. has a net margin of -- compared to Alto Neuroscience, Inc.'s net margin of --. Alto Neuroscience, Inc.'s return on equity of -45.08% beat CEL-SCI Corp.'s return on equity of -266.61%.

Alto Neuroscience, Inc. has a consensus price target of $29.25, signalling upside risk potential of 117.8%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 558.92%. Given that CEL-SCI Corp. has higher upside potential than Alto Neuroscience, Inc., analysts believe CEL-SCI Corp. is more attractive than Alto Neuroscience, Inc..

Alto Neuroscience, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Alto Neuroscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alto Neuroscience, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Alto Neuroscience, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Alto Neuroscience, Inc.'s net income of -$14.2M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Alto Neuroscience, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alto Neuroscience, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -- compared to Alto Neuroscience, Inc.'s net margin of 31.72%. Alto Neuroscience, Inc.'s return on equity of -45.08% beat Eli Lilly & Co.'s return on equity of 106.26%.

Alto Neuroscience, Inc. has a consensus price target of $29.25, signalling upside risk potential of 117.8%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,056.70 which suggests that it could grow by 4.59%. Given that Alto Neuroscience, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Alto Neuroscience, Inc. is more attractive than Eli Lilly & Co..

Alto Neuroscience, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Alto Neuroscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.50 per share. Alto Neuroscience, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Alto Neuroscience, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Alto Neuroscience, Inc.'s net income of -$14.2M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Alto Neuroscience, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 49.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alto Neuroscience, Inc. is -- versus 15.50x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -- compared to Alto Neuroscience, Inc.'s net margin of 21.32%. Alto Neuroscience, Inc.'s return on equity of -45.08% beat Pfizer Inc.'s return on equity of 10.84%.

Alto Neuroscience, Inc. has a consensus price target of $29.25, signalling upside risk potential of 117.8%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 11.56%. Given that Alto Neuroscience, Inc. has higher upside potential than Pfizer Inc., analysts believe Alto Neuroscience, Inc. is more attractive than Pfizer Inc..

Alto Neuroscience, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Alto Neuroscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.61% to investors and pays a quarterly dividend of $0.43 per share. Alto Neuroscience, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Alto Neuroscience, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Alto Neuroscience, Inc.'s net income of -$14.2M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Alto Neuroscience, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 15.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alto Neuroscience, Inc. is -- versus 2.37x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.